α-Blocker Therapy: Current Update

Reviews in Urology

Steven A Kaplan¹ 

[1] Department of Urology, College of Physicians & Surgeons, Columbia University, New York, NY

关键词: Benign prostatic hyperplasia;    Lower urinary tract symptoms;    α-Blockers;    Phenoxybenzamine;    Prazosin;    Doxazosin;    Terazosin;    Tamsulosin;    Alfuzosin;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

α-Blockade is the predominant form of medical therapy for the treatment of symptomatic bladder outlet obstruction due to benign prostatic hyperplasia (BPH). Recent research has shown that there is a series of α1 receptor subtypes present in humans and that the α1A subtype appears to play a primary role in mediating prostatic smooth muscle contraction. Recent interest has therefore focussed on the development of agents specific to this α1A receptor subtype. The approval by the Food and Drug Administration of tamsulosin, an α1A-specific antagonist, offers physicians in the United States the opportunity to prescribe a selective α1-blocker for the treatment of BPH. Tamsulosin offers a pharmacologic means to better target α-blockade specifically to the prostatic smooth muscle and spare the vascular smooth muscle. Use of this agent has resulted in a lower incidence of clinically relevant effects on blood pressure or heart rate and minimal cardiovascular adverse effects.

【 授权许可】

Unknown